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Follicular helper CD4 T (Tfh) cells play an essential role in the formation of germinal centers
(GCs), where mature B cells proliferate, differentiate, and provide long-term protective
humoral responses. Despite the extensive phenotypic characterization and identification
of human Tfh cell subsets, their spatial positioning at tissue level is not well understood.
Here, we describe a quantitative multiplexed immunofluorescence approach allowing for
the comprehensive in situ characterization of Tfh cells in human tonsils and lymph nodes
(LNs) from individuals with angioimmunoblastic T-cell lymphoma (AITL). We have
developed eight multiplexed panels comprising a spectrum of Tfh cell markers, like PD-
1, CXCR5, and ICOS, along with transcription factors (Bcl6, Tbet, GATA3), to assess their
expression, frequencies, spatial distribution and co-localization in a quantitative manner.
Combined analysis of relevant markers revealed the presence of several Tfh cell subsets at
tissue level based on the differential expression of surface receptors, nuclear factors as
well as their distinct localization within the follicular areas. Interestingly, we found a
considerable amount of tonsillar Tfh cells expressing high levels of the Th2 regulator
GATA3. The co-expression of GATA3, CXCR5, and BCL6, points to an important role of
GATA3 for the generation of effector human Tfh cells. Furthermore, our data revealed
significantly different Tfh cell profile signatures between health and disease. Therefore, our
imaging platform generates meaningful information for the in situ characterization of
human Tfh cells and could provide the base for future studies aiming to a comprehensive
understanding of Tfh cell tissue heterogeneity.
Keywords: follicular helper T cells, multiplexed imaging, heterogeneity, germinal center, tonsil, angioimmunoblastic
T-cell lymphomaorg February 2021 | Volume 11 | Article 6076261
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Tfh cells is a highly specialized subset of CD4+ T cells playing a
critical role in protective immunity by helping B cells to produce
antibodies against foreign pathogens. They are located in secondary
lymphoid organs (SLOs), including tonsil, spleen and lymph nodes.
These organs accommodate numerous lymphocytes, organized in
T- and B-cell zones with Tfh cells found exclusively in the B-cell
zone (1). Therefore, Tfh cells are essential for the formation of a GC
reaction and they provide developmental cues for the differentiation
of antigen-selected high-affinity GC B cells into memory B cells and
plasma cells (2, 3) Tfh cells express unique i) phenotype,
characterized by CCR7lo, CXCR5hi, PD-1hi, CTLA-4hi, ICOShi,
CD95hi, CD40Lhi, and Bcl-6hi expression (4–6) which is
preserved across different species (mouse, human, and non-
human) (7–10), ii) transcriptome signature (10–12) and iii)
function, mediated by both surface receptor interactions and
soluble factors like IL-21, IL-4, CXCL13 (3, 10, 13, 14). Within
the germinal center Light Zone (LZ), the interaction between Tfh
cells, B cells, follicular dendritic cells (FDC) and antigen provides
appropriate signals for further division of B cells and their somatic
hypermutation in the Dark Zone (DZ) (15, 16). By controlling the
mutation diversity of GC B cells, the strength of the delivered Tfh
help is a critical factor for the excessive somatic hypermutation
required for the development of broadly neutralizing antibodies
(17). More recently, circulating counterparts of GC Tfh cells have
been identified (cTfh), a cellular compartment composed of
phenotypically and functionally distinct subsets (18). Although
the lineage association between the GC- and cTfh cells is not
clear, analysis of cTfh dynamics has been successfully used as a
surrogate of GC reactivity under certain circumstances (19).
The development of Tfh cell is a multi-step process where a
combination of biological factors including antigen recognition,
local inflammatory signals, co-stimulatory, and co-inhibitory
signals as well as soluble mediators like cytokines and
chemokines play a critical role (20). Upon antigen recognition,
dendritic cells and cytokines (e.g., IL6 and IL2) are important
factors for the initiation of Tfh cell differentiation (20, 21). The
continuous differentiation of Tfh cells is dependent on T-B cell
interactions (22, 23) and is mediated by molecules like CD80 and
CD86, the ligands for CD28 (24) and ICOSL (23). This dynamic,
multi-phase process, presumably leads to Tfh subsets with
different functions (25, 26). Furthermore, the identification of
follicular CD4 T cells with regulatory function (Tfr) (27, 28) adds
to the complexity of the follicular CD4 T-cell pool. Therefore, the
in situ heterogeneity of the Tfh cellular compartment represents
a critical aspect of their biology and role in relevant diseases.
Whether the phenotypic and functional heterogeneity of Tfh
cells is associated with a unique compartmentalization and
spatial positioning and whether these Tfh cell dynamics are
stochastic or not, is not well elucidated and needs further
investigation. In addition to classical Tfh markers, the use of
mouse models has revealed the important role of transcriptional
factors like BCL6 (29) and TOX2 (30) for Tfh cell development.
Although initially considered as highly/terminally differentiated,
there is growing evidence that Tfh cells display substantialFrontiers in Immunology | www.frontiersin.org 2flexibility and plasticity and may share characteristics of other
effector CD4+ Th cell populations (31, 32). Tfh cells may also co-
express other transcription factors, such as TBET, GATA3 and
ROR-gt, which are expressed by Th1, Th2, and Th17 cells (33). It
has been recently reported that under conditions of infection,
Tfh cells express the Th1 transcription factor TBET (34). KLF2
can suppress the differentiation of Tfh cells by inducing TBET and
GATA3 (35) while the absence of STAT3 accompanied by the
induction of GATA3, inhibits the initial differentiation of Tfh cells
(36). On the other hand, increased production of IL-4 has been
associated with a GATA+BCL6+ Tfh phenotype which is
regulated by Ets1 (37). Whether the expression of such
transcriptional factors reflects a possible lineage association
between Tfh cells and other Th effector subsets is not well
understood. Furthermore, the possible role of Tfh cells
expressing these transcription factors in human immune
responses and disease pathogenesis needs investigation.
Neoplasms derived from Tfh cells have been described. The
prototype of these is angioimmunoblastic T-cell lymphoma
(AITL), an overall rare lymphoma entity but one of the most
common forms of neoplasms derived from mature T cells
occurring in adults (38–40). AITL usually manifests as a
systemic disease in adults or elderly individuals who present
with generalized peripheral lymphadenopathy, often with
extranodal involvement, various systemic symptoms and
immune abnormalities like polyclonal hypergammaglobulinemia
and Coombs-positive hemolytic anemia. It usually runs an
aggressive clinical course and the median survival is <3 years
(41). Tissues involved by AITL are typically enlarged by a
polymorphous infiltrate comprising an abundant reactive
microenvironment, and a minor component of neoplastic Tfh
cells (42). Tfh lymphomas feature a characteristic mutational
landscape associating mutations in epigenetic modifyers (TET2,
DNMT3A, IDH2), RHOA and other T-cell receptor signaling
genes (43–46).Here, we sought to characterize subsets of reactive
Tfh cells in the tonsil and neoplastic Tfh cells in the context of
angioimmunoblastic T cell lymphoma (AITL). A gradually
increasing use of mulpiplex imaging assays both in discovery
research and diagnostic pathology has been observed the recent
years (47–49). Compared to traditional immunohistochemistry
assays, multiplexed imaging has the advantage of the simultaneous
detection of several biomarkers for the characterization of tissue
elements including effector cells, stromal cells, cytokine milieu,
and tissue architecture at a single focal plane. Therefore,
multiplexed imaging reduces the possibility for interpretive
errors, especially when rare cell populations are under
investigation, while preserves valuable tissue material for further
analysis. In combination with advanced computational tools,
multiplexed imaging can provide a high dimension, high
resolution quantitative analysis of tissue cell dynamics and
microenvironment (50). We have developed a whole-slide
multiplexed immunohistochemistry (mIHC) platform,
employing eight antibody panels, to study and characterize the
Tfh cells in situ. We provide data showing significant differences
between tonsillar and AITL Tfh cells regarding the expression of
particular markers.February 2021 | Volume 11 | Article 607626
Ioannidou et al. In Situ Tfh Cell HeterogeneityPATIENTS AND METHODS
Tissue Samples
Human tonsils were obtained from children who underwent
routine tonsillectomy at the Hôpital de l’Enfance of Lausanne.
The neoplastic tissue samples were retrieved from the archives of
the Institute of Pathology of Lausanne University Hospital, from
patients diagnosed with AITL. This monocentric research project
was approved by the Ethical Committee of the Canton de Vaud,
Switzerland - protocol number 123-13 and conducted according
to the principles of the Declaration of Helsinki. Written
informed consent was obtained from all participants.
Staining Procedures
Sequential 4 mm thick sections from formalin-fixed, paraffin
embedded (FFPE) blocks were cut and prepared on Superfrost
glass slides (Thermo Scientific, Waltham, MA, Ref.
J1800AMNZ), dried overnight at 37°C and stored at 4°C for
conventional IHC and fluorescent mIHC staining. The slides
were then heated on a metal hotplate (Stretching Table, Medite,
Burgdorf, OTS 40.2025, Ref. 9064740715) at 55°C for 15 min, a
melt ing step of paraffin for proper adherence and
deparaffinization of tissue sections. All the chromogenic and
fluorescent IHC were performed on the Ventana Discovery Ultra
Autostainer from Roche Diagnostics.
Chromogenic Staining
It was performed on tissue sections using the ChromoMap DAB
detection Kit (Inhibitor CM, DAB CM, H2O2 CM, Copper CM)
(Ref. 750-159, Ventana Medical System, Tucson, AZ). Briefly, the
slides after the melting step of paraffin, were followed by a pre-
treatment heat-induced epitope retrieval at 95°C. Then, they
were incubated with an inhibitor solution for 4 min to quench
endogenous peroxidases activity and the Ventana dilution buffer
(Ref. ADB250, from Roche) was used as a blocker for unspecific
binding, for 20 min incubation at RT. Next, the slides were
incubated with primary antibodies, applied either manually or
with ready to use Roche Ventana dispensers at 37°C, for the
validated optimum time. This was followed by incubation withFrontiers in Immunology | www.frontiersin.org 3horseradish peroxidase (HRP)-conjugated mouse or rabbit
secondary antibodies, DAB revelation and hematoxylin
counterstaining (Roche, Ref. 790-220B) for 8 min. Then, the
slides were washed and dehydrated through immersion in
successive baths (2 min each) with an ascending series of
ethanol, followed by increasing concentration of xylene before
coverslip mounting. The slides were finally scanned by the
whole-slide scanner NanoZoomerS60, Hamamatsu (serial #
C13210-01, Hamamatsu, Hamamatsu City, Japan).
Immunofluorescence Staining
The procedure consisted of consecutive rounds of antigen
retrieval, antibody blocking steps (using the Opal blocking/
antibody diluent solution) for non-specific binding of
antibodies, staining with primary antibodies (all antibodies,
clones and dilutions used in this study are listed in Table 1),
incubation with secondary HRP-labeled antibodies, then
detection with optimized fluorescent Opal tyramide signal
amplification (TSA) dyes (Opal 7-color Automation IHC kit,
from Akoya, Ref. NEL821001KT) and repeated antibody
denaturation cycles, as previously described (51–53). Tissue
sections were then counterstained with Spectral DAPI from
Akoya for 4 min, rinsed in water with soap and mounted
using DAKO mounting medium (Dako/Agilent, Santa Clara,
CA, USA, Ref. S302380-2).
Multispectral Scanning and Image
Acquisition
Multispectral images (MSI) were acquired using the latest Vectra
Polaris imaging system from Akoya. All images were recorded
using a 20x magnification. The Phenochart 1.0.12 software
(Akoya), a whole-slide contextual viewer with annotation
capability was used for navigation around slides and
identification of Regions Of Interest (ROIs), for high-
resolution multispectral acquisition. A spectral library
containing the emitting spectral profile of all six reporter
fluorophores (in monoplex staining) and of DAPI, plus the
autofluorescence signal present in FFPE tissues, obtained from
a target tissue of relevant slide, was created with the NuanceTABLE 1 | Antibodies used in the multiplexed panels.
Antibody Clone Tissue Specificity Species Source Dilution
BCL6 GI191E/A8 Nuclear Mouse Roche/dispenser Prediluted
CD3 2GV6 Cytoplasmic/Membranous Rabbit Roche/dispenser Prediluted
CD4 SP35 Membranous Rabbit Roche/dispenser Prediluted
CD8 C8/144B Membranous Mouse DAKO/M7103 1:30
CD10 SP67 Membranous Rabbit Roche/dispenser Prediluted
CD21 EP 3093 Membranous Rabbit Roche/dispenser Prediluted
CD30 Ber-H2 Membranous Mouse DAKO/M0751 1:30
CD68 PG-M1 Cytoplasmic Mouse DAKO/M0876 1:200
CXCL13 Polyclonal Extracellular/Cytoplasmic Rabbit Thermofisher/PA5-79106 1:300
CXCR5 Polyclonal Cytoplasmic/Membranous Rabbit Abcam, 46218 1:500
GATA3 L50-823 Nuclear Mouse Biocare Medical /405 1:25
ICOS SP98 Membranous Rabbit Abcam 105227 1:50
PAX5 SP34 Nuclear Rabbit Roche/dispenser Prediluted
PD-1 NAT 105 Cytoplasmic/Membranous Mouse Biocare Medical/3137 1:100
TBET MRQ-46 Nuclear Rabbit Roche/dispenser PredilutedFebruary 2021 | Volume 11 | Article 607626
Ioannidou et al. In Situ Tfh Cell HeterogeneityImage Analysis software (Akoya). The subsequent imaging and
analysis were performed on selected annotations and specific
MSI fields, representing the 30–40% of the tissue. The whole
tissue slides were pre-scanned at a 10x magnification and
approximately 20–40 regions were selected for the acquisition
of high-power (20x) MSI.
Image Analysis and Quantification
MSI were analyzed using the inForm image analysis software,
version 2.4.8 from Akoya. Firstly, the images were unmixed and
were segmented into specific tissue ROIs [e.g., Germinal center
(GC), LZ, DZ, Extrafollicular area (ExtraFC), and No Tissue] for
the tonsils’ analysis, using the appropriate training components
like BCL6, CD10, and PD-1 for defining the GC (Figure 1A).
Similarly, for the Tumor and No Tissue of the lymphoma
staining analysis, this tissue discrimination reflectedFrontiers in Immunology | www.frontiersin.org 4accordingly the selected lymphoma areas from the non-
neoplastic necrotic tissue or the holes lacking structural
integrity. The segmentation was based on selected training
markers and DAPI expression and taking into consideration
the autofluorescence signal of the tissue, after manually drawing
training regions on each image. The training of the segmentation
algorithm was done in two ways: i) for images/panels where the
“quality” of the signal was comparable among the tissues, a
training pool of images was created by combining ROIs (20–40
on average) from all three tonsils and the trained algorithm was
applied to segment different ROIs from the original three images
and ii) for images with no comparable staining quality, ROIs
from a certain tissue were used to train the algorithm and
analysis of remaining ROIs from the same image. Parameters
like the quality of used tissues per se and distinct features of used
areas for training could introduce some bias using this path forA B D
C E
FIGURE 1 | The imaging platform generates highly reproducible imaging data. (A) The annotated ROIs for an imaged tonsil section are shown using annotation
boxes of a fixed size. White arrows mark ROIs where more than one box was applied to cover the ROI and the red arrow marks a box that covers two ROIs.
(B) The images of annotated ROIs were unmixed and segmented into specific tissue categories (Germinal center-GC and ExtraFollicular area-ExtraFC), followed by
cell segmentation based on the DAPI staining. (C) CD4+ T cells were identified using the phenotype approach, assigning approximately 100 cells per phenotype
(green dots). Histiocytes which also express CD4, were recognized by their morphology and phenotyped as “other cells” (cyan dots) and excluded from the analysis.
With this strategy, overestimation of CD4+ T cells was avoided. (D) The number of total cells within the total segmented germinal centers, normalized by the imaged
surface area in mm2, for each of the main six multiplexed panels used are shown. (E) The reproducibility of calculated frequencies for representative cell phenotypes
across the different multiplexed panels for one imaged tonsil is shown. Horizontal lines depict mean values of each marker calculated across the six panels and bars
depict standard deviation.February 2021 | Volume 11 | Article 607626
Ioannidou et al. In Situ Tfh Cell Heterogeneitytraining. In preliminary studies, it was observed that the
possibility of creating false positive or negative data
(segmented ROIs) by applying the first path of training across
images with non-comparable staining quality was higher
compared to the use of well-defined ROIs from the same
tissue. ROI segmentation with training accuracy (provided by
inForm) higher than 90 was used. Cell segmentation accuracy
was verified by comparing manually counted imaged cells to the
ones generated by the program after cell segmentation.
Individual cells were segmented using the counterstained-based
adaptive cell segmentation algorithm, with the help of cytoplasm
and membrane markers. There might be a minor potential
increase/decrease in the percentages, either because big cells/
clusters of cells might not be well segmented and therefore not
phenotyped as positive, or because the DAPI intensity of some
cells might be very low, below the decided parameters, and
consequently not get detected. In general, we found a high
level of agreement (> 90%) between the manually and
segmented cells. Following tissue and cell segmentation, the
phenotyping configuration was used, by assigning around 100
cells to the positive phenotype for each marker, while selecting
additional 100 cells characterized as “other” for the negative
phenotype, choosing across several images. A similar approach
using a binary classification scheme, into a positive and a
negative categories was recently published (52). CD4 apart
from staining CD4 T lymphocytes, also stained histiocytes. The
histiocytes recognized by their size and morphology were
phenotyped in CD4 immunostaining as “other cells” and
therefore were excluded from the analysis (Figure 1B).
However, because of the proximity of cells and the fact that
adjacent cells might share signal, a small phenotyping error of
1% by the software in a few images was calculated. Individual
algorithms were created for each marker on a set of training
images, which were applied afterwards on all selected
annotations of the whole-slide MSI. The quantification was
based on PhenoptrReports from Akoya, an automated R-script
platform, where separated merged cell segmentation data,
retaining the same tissue segmentation, were created for each
phenotyped marker and were consolidated afterwards. The
different combinations of phenotyped populations were defined
and the analysis was run creating reports, which contained the
number of analyzed fields (slide summary), cell counts, cell
percentages, and cell densities.
Cell Phenotyping With Mass
Cytometry (Cytof)
Cryopreserved tonsil mononuclear cells (TNMCs) were thawed
and resuspended in complete RPMI medium [Gibco; Life
Technologies; 10% heat-inactivated FBS (Institut de
Biotechnologies Jacques Boy), 100 IU/ml penicillin, and 100
µg/ml streptomycin (BioConcept)]. Cells were washed in PBS
and then incubated for 30 min with a 50 ml antibody cocktail of
cell surface metal conjugated antibodies (Table 2). Cells were
washed and fixed for 10 min at RT with 2.4% PFA. Next, cells
were permeabilized for 45 min at 4°C with Foxp3 Fixation/
Permeabilization kit (eBioscience), washed and stained at 4°C forFrontiers in Immunology | www.frontiersin.org 530 min with a 50 ml cocktail of T-bet, BCL-6, and GATA-3 metal
conjugated antibodies. Cells were washed and fixed for 10 min at
RT with 2.4% PFA. Total cells were identified by DNA
intercalation (1 mM Cell-ID Intercalator, Fluidigm/DVS
Science) in 2% PFA at 4°C for 1 h. The list of metal isotopes
antibodies used are listed in Table 1. Labeled samples were
assessed by the CyTOF1 instrument that was upgraded to
CyTOF2 (Fluidigm) using a flow rate of 0.045 ml/min. FCS
files were normalized to the EQ Four Element Calibration Beads
using the CyTOF software. Data were analyzed using Fluidigm
Cytobank software package (Cytobank, Mountain View, CA).
Statistical Analysis
Data were analyzed using one-way ANOVA and non-parametric
tests. Graphs were generated using the GraphPad Prism 8.3.0
program. The bar graphs shown in Figures 5A, B were generated
using Python and Python modules Pandas and Seaborn. The
color intensity of each bar was created based on the frequency
(%) of the corresponding marker analyzed.RESULTS
Development of a Multiplex Imaging
Platform for the In Situ Characterization
of Human Tfh Cells
A comprehensive understanding of Tfh cell heterogeneity
requires the simultaneous detection and analysis of several
relevant molecular markers. To this end, we have used
antibodies against several GC and Tfh cell markers (Table 1)






and TF-GATA3TBETBCL6PD-1CXCR5CD4DAPI) (Table 3).
Tonsillar tissues were used for the establishment of the panels
using the experimental strategy shown in the Supplementary
Figure 1. Single tissue staining (monoplex) was used for theTABLE 2 | Antibodies used for the Mass Cytometry phenotypic characterization
of tonsillar derived cells.
Antibody Metal Clone Company Cat N.
CD8 113ln RPA-T8 Biolegend 301018
CCR6 141Pr 11A9 DVS 3141014A
CD19 142-Nd HIB19 DVS 3142001B
GATA-3 146Nd TWAJ ThermoFisher 14-9966-82
CXCR5 153-Eu RF8B2 DVS 3153020B
CXCR3 154Sm GO25H7 Biolegend 353718
CD45RO 165HO UCHL1 DVS 3165011B
CD45RA 169-Tm HI100 DVS 3169008B
CD3 170-Er UCHT1 DVS 3170001B
PD-1 174Yb EH12.2H7 DVS 3174020B
CD4 176-Yb RPA-T4 DVS 3176010B
Cisplatin 198Pt Cell-ID DVS 201198February 2021 | Volume 11 | Article 607626
Ioannidou et al. In Situ Tfh Cell Heterogeneityoptimization of each antibody used. Using the optimized
experimental conditions as a reference, six-plex panels were
developed, with an optimized panel shown in Supplementary
Figure 2. Using area and cell segmentation combined with a
quantitative approach (Figures 1A–C), we analyzed the
prevalence of relevant tonsillar populations. First, the number
of total cells (identified by DAPI positive nuclei) within the
segmented GCs, normalized by the total GC imaged surface area
in mm2, was calculated for each one of the main six multiplexed
panels used. Accumulated data for three tonsils analyzed are
shown in Figure 1D. The total number of GCs and associated
GC cells analyzed might be different between panels, consideringFrontiers in Immunology | www.frontiersin.org 6that the sections were taken at different depths in the FFPE tissue
blocks. Of note, our assays generated highly reproducible data
regarding the frequencies of the common markers used across
the six panels (Figure 1E and Supplementary Figures 3A, B).
Identification of Major Tonsillar Follicular/
GC Cell Types
First, we analyzed the main follicular and particularly GC cell
types, including B cells, follicular dendritic cells (FDC), T cells,
and macrophages (tingible body macrophages). As expected, the
majority of cells expressed high levels of CD21 (abundant in B
cells) and PAX5 (a transcription factor found in B cells)
(Figure 2A). Specifically, approximately 79% of total GC cells
were PAX5+ and 70% of PAX5+ cells co-expressed CD21
(Supplementary Figure 3A). We identified the FDC backbone
of the GC area based on its circumferential meshwork staining
pattern for CD21 (Figure 2A). The expression pattern of CD21
and PAX5 guided the identification of GC and non-GC follicular
areas (Figure 2A). Regarding T cells, CD3+ cells made up the
24% of total cells (panel TFH 1) in the GC (Figures 2B, C and
Supplementary Figure 3A). We identified and quantified “real”
CD4+ T lymphocytes by excluding histiocytes, being also
positive to the CD4 antibody, as explained in the Methods
section and shown in Figure 2C. Approximately, 23% of the
total GC cells were positive for CD4 (panel TFH 1) (Figure 2B
and Supplementary Figure 3A). Around 1% of the total GC cells
were identified as CD3+CD8+ (Figure 2B and Supplementary
Figure 3A). CD68 that labels macrophages appeared to highlight
scattered macrophages within the GC at a percentage of 3.7%
(Figures 2B, C). As expected, our collective analysis focusing on
follicular CD4+ T cell revealed the dominance of subsets
expressing classic Tfh markers (e.g., PD-1, BCL6, CXCR5, and
ICOS) (Table 4). Altogether, our data show that the described
platform provides solid data for the in situ analysis of GC
immune cells, especially Tfh cells.
Characterization of Tonsillar Tfh Cells
Tfh cells are defined by a unique phenotype characterized by the
high surface expression of several markers including CXCR5
(54), PD-1 (55), and ICOS (56). We started investigating the in
situ heterogeneity of Tfh cell using both surface and nuclear
markers. We found that 78% of total GC cells were positive for
CXCR5 (Supplementary Figure 3A). Using three different
thresholds (low, dim, and high, defined by intensity counts of
5, 7, and 9, respectively), we found that CXCR5high cells were
located in the GC and at the Mantle Zone (MZ) admixed with
medium and low CXCR5 expressing cells, while CXCR5low cells
were detected mainly in the ExtraFC area (Figure 3A and
Supplementary Figures 4A, B, D). Quantitative analysis
revealed that approximately 20% of total GC cells expressed a
PD1+CD4+ phenotype (Table 4) while 85% of PD1+CD4+ T
cells were CXCR5+ (data from TFH 4 and TF panels, Table 4).
Therefore, simultaneous analysis of CD4 and PD-1 is a reliable
way for identification of GC Tfh cells. With regard to their
localization, a distinct polarization of PD-1+ CD4+ T cells
towards the apical light zone of the GC was observedTABLE 3 | Multiplexed panels’ information.
Panel Order Antibodies Opal Fluorophores Dilution
Immune 1 CD3 Opal 520 1/400
2 CD8 Opal 620 1/150
3 CD68 Opal 480 1/700
4 CD4 Opal 690 1/150
5 DAPI Spectral DAPI
Panoramic 1 PD-1 Opal 620 1/100
2 CD8 Opal 480 1/500
3 PAX5 Opal 570 1/100
4 CD4 Opal 690 1/100
5 CD21 Opal 520 1/300
6 DAPI Spectral DAPI
TFH 1 1 CD3 Opal 620 1/300
2 PD-1 Opal 650 1/200
3 CXCL13 Opal 520 1/150
4 BCL6 Opal 570 1/500
5 CD4 Opal 690 1/150
6 DAPI Spectral DAPI
TFH 2 1 PD-1 Opal 570 1/600
2 CD10 Opal 650 1/300
3 BCL6 Opal 520 1/125
4 CD30 Opal 620 1/200
5 CD4 Opal 690 1/150
6 DAPI Spectral DAPI
TFH 3 1 PD-1 Opal 620 1/500
2 ICOS Opal 520 1/100
3 BCL6 Opal 570 1/850
4 CD10 Opal 650 1/400
5 CD4 Opal 690 1/250
6 DAPI Spectral DAPI
TFH 4 1 PD-1 Opal 620 1/350
2 CXCR5 Opal 520 1/100
3 GATA3 Opal 570 1/850
4 CXCL13 Opal 650 1/400
5 CD4 Opal 690 1/250
6 DAPI Spectral DAPI
GATA3 1 CD8 Opal 620 1/400
2 GATA3 Opal 570 1/150
3 CD4 Opal 690 1/100
4 DAPI Spectral DAPI
TF 1 GATA3 Opal 620 1:50
2 TBET Opal 480 1/400
3 BCL6 Opal 520 1/100
4 PD-1 Opal 570 1/100
5 CXCR5 Opal 690 1/100
6 CD4 Opal 780 1/25
7 DAPI Spectral DAPIThe markers (1 to 6/7) are depicted in the order they were applied for immunostainings
with their paired fluorophores and respective dilutions. T follicular cell multiplexed panel
(TFH) and Transcription factor (TF) panel.February 2021 | Volume 11 | Article 607626
Ioannidou et al. In Situ Tfh Cell Heterogeneity(Figure 3B). We observed that the vast majority of CD4 T cells in
the follicular and GC area express a PD-1high/PD-1dim phenotype
compared to extrafollicular CD4 T cells which are PD-1low
(Supplementary Figures 4C, D). Similar to PD-1, ICOS+ cells
were polarized in the outer rim of the GC adjacent to the MZ
(Figure 3B). Quantitative analysis of ICOS expression showed a
wide overlap with PD-1 (Tfh cells co-expressed ICOS at 73.2%)
(Table 4) in agreement with the critical role of ICOS+ Tfh cells in
GC reactivity (23). Analysis of BCL6, a transcription factor
critical for the development of Tfh cells (57) revealed a wide
expression in the GC area. In line with its expression in B and
Tfh cells, BCL6 was expressed in approximately 80% of total cells
in the GC (Figure 3C and Supplementary Figures 2B, 3A) while
approximately 73% of Tfh cells were positive for BCL6 (Table 4).
CD10, a glycoprotein that is expressed on GC B cells and a subset
of Tfh cells (58) exhibited a positive diffused cytoplasmic and
membranous signal inside the GC at a percentage of 82% from
the total cells (Figure 3C and Supplementary Figure 2B).
Furthermore, 64% of Tfh cells co-expressed CD10, while 53.5%
of Tfh cells expressed a CD4+PD-1+BCL6+CD10+ phenotypeFrontiers in Immunology | www.frontiersin.org 7(Table 4). A considerable expression of CXCL13, the ligand of
CXCR5, was also found with 25% of Tfh cells and 15% of
CD4+PD-1+BCL6+ cells staining for CXCL13 (Table 4).
Altogether, our combinatorial analysis revealed a heterogeneous
pool of Tfh cells with respect to the expression of surface (PD-1,
ICOS, CXCR5, and CD10), nuclear (BCL6) and functional
(CXCL13) markers.
In Situ Phenotyping Reveals a Significant
Expression of GATA3 in Tfh Cells
Next, we sought to investigate the expression of TBET (59) and
GATA3 (60), two major CD4 T-lineage transcription factors, in
the follicular area. Application of a 6-plex panel revealed a
differential localization between BCL6, GATA3 and TBET
(Figure 4A). In contrast to BCL6, a wider distribution, both in
follicular andExtraFC areas, was observed forGATA3while TBET
was almost exclusively found in the ExtraFC area (Figures 4A, B).
Our quantitative imaging showed thatCD4+PD-1+BCL6+GATA3+
T cells were exclusively localized in the GC area (Figure 4B).
Interestingly, we observed a polarization of GATA3+ cells towardsA B
C
FIGURE 2 | Defining germinal center and follicular immune cells. (A) The expression pattern of CD21 and PAX5 (Panoramic panel) guided the identification of the
GC versus the ExtraFC areas. (B) A representative follicular area showing the localization of CD3 (cyan), CD8 (yellow), CD4 (red) and CD68 (orange) and DAPI
positive events (upper left). Individual cell types in a zoomed GC area (dotted line) are shown. (C) Phenotyped images of a follicular area as well as a zoomed area
(inset) showing CD3+CD4+ cells (CD4+ T lymphocytes) (green arrowheads) and other CD3-CD4+CD68+ cells which were considered as stained macrophages (cyan
arrowheads) and excluded from the quantification of the total CD4+ T lymphocytes.February 2021 | Volume 11 | Article 607626
Ioannidou et al. In Situ Tfh Cell Heterogeneitythe light zone, mirroring the distribution of PD-1 expression
(Figure 4C). Analysis of specific populations showed a
heterogeneity of Tfh cells with respect to BCL6 and GATA3
expression. Specifically, 58% of Tfh cells express GATA3 while
only 35.8% of them co-express BCL6 and GATA3 (Figure 4D and
Table 4). Inclusion of CXCR5 in our analysis revealed even higher
heterogeneity of the Tfh cell pool with 33.8% of Tfh cells been
CXCR5+BCL6+GATA3+ (Table 4). We sought to further
characterize the phenotype of GATA3+ Tfh cells using a Cytof
assay (Supplementary Figure 5). Our data showed a significantly
higher frequency ofGATA3+ cells in the PD1hi Tfh cells compared
to other tonsillar CD4 T cell subsets (Figure 4E). The majority of
cells expressed a CXCR3-CCR6- phenotype in all CD4 T cell
subsets analyzed, followed by the CXCR3+CCR6- phenotype
(Figure 4F). A low frequency of cells expressed a CXCR3+CCR6
+ or CXCR3-CCR6+ phenotype (Figure 4F). Altogether, our data
show that determination of Tfh cell heterogeneity requires
investigation of both surface receptors and transcriptional
factors, especially GATA3.Frontiers in Immunology | www.frontiersin.org 8Identification of Tonsillar Tfh Cell
Tissue Signatures
Combining the information collected from all developed panels
can provide comprehensive phenotypic signatures of Tfh cells.
To this end, CD4 and PD-1 were used as “reference” markers
(expression 100%). As it was expected, CXCR5 and BCL6 and
ICOS were the most widely expressed markers (Figure 5A, left
panel). We defined two tonsillar Tfh phenotypic signatures based
on the prevalence of dominant markers CD4+PD-1+BCL6
+CXCR5+ (Signature 1, 69.4% of CD4+PD-1+cells), CD4+PD-
1+BCL6+ICOS+CD10+ (Signature 2, 42.8% of CD4+PD1+
cells), while a less frequent signature found when the CXCL13
and GATA3 was introduced (CD4+PD-1+CXCR5+BCL6
+CXCL13+GATA3+, Signature 3, 13.7% of CD4+PD-1+cells)
(Figure 5B, left panel). Next, the frequency of Tfh cells
expressing the signature 1 with respect to their localization in
DZ, LZ, and MZ areas was analyzed. The vast majority of these
events located in the LZ with a minority (around 4–6%) found in
DZ or MZ (Figure 5C). Therefore, our imaging platform couldTABLE 4 | Collective data from all six developed multiplex panels, with phenotypes combinations after analysis of three tonsils and three selected AITL cases, with
reference to the GC CD4+PD-1+ cells in tonsils and to CD4+PD-1+ cells in the Tumor niche in AITL cases.
(%) Percentages Tonsil 1 Tonsil 2 Tonsil 3 Averages AITL 1 AITL 2 AITL 3 Averages
From Total GC cells From Total Tumor cells
CD4+PD-1+ 24.66 16.16 16.66 19.16 5.83 24.0 50.16 26.66
(%) Percentages with reference to CD4+PD-1+ cell in the GC in the Tumor niche
CD3+CD4+PD-1+ 94.20 95.0 92.50 93.90 97.20 96.40 90.80 94.80
CD4+PD-1+BCL6+ 77.47 71.52 71.55 73.52 49.90 43.25 32.57 41.91
CD4+PD-1+CD10+ 54.95 67.30 69.55 63.93 32.45 24.35 21.65 26.15
CD4+PD-1+ICOS+ 78.90 80.40 60.30 73.20 71.50 88.40 71.40 77.10
CD4+PD-1+CXCR5+ 85.20 83.15 86.40 84.92 63.80 44.60 60.25 56.22
CD4+PD-1+CXCL13+ 23.15 25.65 26.95 25.25 56.40 28.80 65.15 50.12
CD4+PD-1+CD30+ 0.10 0.01 0.01 0.04 8.0 35.50 64.70 36.07
CD4+PD-1+GATA3+ 63.0 59.65 52.1 58.25 32.75 37.05 7.85 25.88
CD4+PD-1+TBET+ 0.10 0 0 0.03 4.60 0.70 0.50 1.93
CD4+PD-1+BCL6+CD10+ 48.35 53.60 58.45 53.46 19.10 12.85 5.0 12.32
CD4+PD-1+BCL6+ICOS+ 62.0 54.60 46.50 54.36 37.10 41.0 22.40 33.50
CD4+PD-1+CD10+ICOS+ 31.50 61.40 35 42.63 27.10 19.60 19.40 22.03
CD4+PD-1+BCL6+CD30+ 0.10 0 0 0.03 4.30 26.10 31.10 20.50
CD4+PD-1+CD10+CD30+ 0 0 0 0 1.80 11.20 3.80 5.60
CD4+PD-1+BCL6+CXCL13+ 12.20 20 13.40 15.20 16.70 8.10 19.70 14.83
CD4+PD-1+CXCR5+CXCL13+ 26.70 15.50 19.10 20.43 37.20 14.80 42.60 31.53
CD4+PD-1+GATA3+CXCL13+ 16.10 11.40 11.60 13.03 9.10 8.50 3.50 7.03
CD4+PD-1+CXCR5+GATA3+ 51.50 48.0 45.20 48.23 22.65 13.90 4.70 13.75
CD4+PD-1+CXCR5+BCL6+ 57.80 64.30 64.80 62.30 51.70 26.50 35.30 37.83
CD4+PD-1+CXCR5+TBET+ 0 0 0 0 2.80 0.20 0.20 1.06
CD4+PD-1+BCL6+TBET+ 0 0 0 0 2.0 0 0 0.66
CD4+PD-1+BCL6+GATA3+ 36.0 34.20 37.30 35.83 27.40 20.60 3.20 17.06
CD4+PD-1+TBET+GATA3+ 0 0 0 0 1.70 0.30 0 0.66
CD4+PD-1+BCL6+CD10+ICOS+ 26.0 43.20 27.40 32.20 16.20 10.80 5.40 10.80
CD4+PD-1+BCL6+CD10+CD30+ 0 0 0 0 1.80 11.20 3.80 5.60
CD3+CD4+PD-1+BCL6+CXCL13+ 11.60 19 12.40 14.33 16.70 7.90 19.40 14.66
CD4+PD-1+CXCR5+CXCL13+GATA3+ 13.70 7.70 6.20 9.20 4.90 2.80 1.50 3.066
CD4+PD-1+CXCR5+BCL6+TBET+ 0 0 0 0 1.50 0 0 0.50
CD4+PD-1+CXCR5+BCL6+GATA3+ 32.10 32.20 37.20 33.83 24.10 11.0 2.90 12.66
CD4+PD-1+CXCR5+TBET+GATA3+ 0 0 0 0 0.90 0 0 0.30
CD4+PD-1+BCL6+TBET+GATA3+ 0 0 0 0 0.70 0 0 0.23
CD4+PD-1+CXCR5+BCL6+TBET+GATA3+ 0 0 0 0 0.60 0 0 0.20February 2021 | Volume 11 | Article 607626
Ioannidou et al. In Situ Tfh Cell Heterogeneityprovide the base for further understanding of the heterogeneity
of Tfh cell in disease.
Different Tfh Core Signatures Between
Tonsillar and Neoplastic Lymph Node
Tissues
Next, we aimed to assess the Tfh phenotypic signatures in lymph
nodes from three AITL individuals with different mutational status
(Table 5). As expected an altered distribution of Tfh cells was found
compared to tonsils (Supplementary Figure 6). Specifically, a
polarized Tfh cell distribution within GC as seen in tonsils wasFrontiers in Immunology | www.frontiersin.org 9missing (Supplementary Figure 6) while a less structured clustering
of Tfh cells was evident in areas characterized by sequestration of
BCL6 positive cells (Figure 5D), a profile associated with the
frequency of tumor cells inferred from the VAF of tumor specific
mutations (RHOA G17V VAF and IDH2 VAF) (Table 4 and
Supplementary Figure 6). Furthermore, the skewed distribution of
BCL6, GATA3, and TBET found in tonsils was missing in AITL
LNs (Supplementary Figure 7A). Similar to tonsils, application of
the mIHC panels generated highly reproducible data for the AITL
LNs (Supplementary Figure 7B). As it was expected, a higher
frequency of PD1+CD4+ T cells was found in LNs (29%) comparedFebruary 2021 | Volume 11 | Article 607626A B
C
FIGURE 3 | Detection of Tfh cell subsets in human tonsils. (A) CXCR5+ cells and their localization in human tonsil assessed by IHC (upper left panel) and by
immunofluorescence (upper right and lower panels). The borders of GC are shown by dotted lines. CXCR5 was strongly expressed especially in the mantle zone
(MZ). CXCR5 is expressed in B cells (CD4-CXCR5+) as well as in a subset of CD4+T cells in the GC. (B) Immunofluorescence image showing distinct follicular areas
(MZ, DZ, LZ). The MZ area is indicated by dotted lines (left panel). Polarization of PD-1+ cells in the LZ of the GC was observed in most of the follicles analyzed. The
localization of ICOS (right panel) and ICOS+PD-1+ (lower panel) cells is shown. A similar polarization pattern was observed for both antigens. (C) Representative
images showing the co-expression of Tfh cell markers (PD-1, ICOS, BCL6, and CD10) in a GC (panel TFH 3).
Ioannidou et al. In Situ Tfh Cell Heterogeneityto tonsil GC (19%) (Table 4 and Supplementary Figure 8A). A
heterogeneity across the three cases was observed, concerning
especially the CXCL13 and GATA3 expression (Supplementary
Figure 8A). CD4 T cells was the dominant immune cell type in the
tumor area while other immune cells (CD8, CD21) were less
frequent (Supplementary Figure 8A). Although the sample size
analyzed was not sufficient for the extraction of statistically
significant data, we consistently found differences between tonsils
and lymph nodes when several Tfh biomarkers were analyzed
(Figure 5A and Table 3). Specifically, we found lower frequency
of Tfh cells expressing Bcl6 (41.9 vs 73.5), CD10 (26.15 vs 63.9), and
GATA3 (25.88 vs 58.25) in LNs compared to tonsils (Figure 5A and
Supplementary Figure 8B). In contrast, a higher frequency of
CXCL13+ Tfh cells was found in LNs compared to tonsils (50.12 vs
25.5) (Figure 5A and Supplementary Figure 8B). Approximately
5% of non-T cells in the tumor area were CD30+. Interestingly, a
relatively high frequency of Tfh cells were positive for CD30, aFrontiers in Immunology | www.frontiersin.org 10receptor often found in AILT (61–63), in LNs (36%) while normal
Tfh cells in tonsil GC very rarely coexpressed CD30 (0.04%) (Table
4). Analysis of the three aforementioned Tfh cell signatures revealed
a different pattern in AITL compared to tonsils (Figure 5B).
Interestingly, a higher frequency of Tfh cells was found to express
signature 1 and 2 (Figures 5B, D) while the difference was less
evident for the signature 3 (13.7 vs 1.5) in tonsils compared to AITL
LNs (Figure 5B). Therefore, the altered, less structured localization
associated with a differential expression of Tfh cell subsets could
represent biological factors contributing to the heterogeneity of the
Tfh cell compartment in AITL patients.DISCUSSION
Similar to a previous study (64), we have employed a multiplexed
immunofluorescence approach to assess the in situ distributionA B
D
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FIGURE 4 | Expression of transcription factors in tonsillar Tfh cell subsets. (A) Representative, low-magnification immunofluorescent images showing the distribution
of CXCR5, PD-1, BCL6, GATA3 and TBET in a tonsil. (B) The prevalence (expressed as % of total cells in the corresponding area) of cells positive for PD-1, BCL6,
GATA3 or their combinations in GCs and ExtraFC areas is shown. Follicular areas (n = 5) from three tonsils were analyzed. (C) The distribution of GATA3+ cells in
GC areas, judged by the BCL6 staining profile, is shown. A polarization of GATA3+ cells towards the LZ, mirroring the distribution of PD-1 expression was
consistently was found. (D) Representative images showing the co-expression of relevant markers (TF panel) in tonsil GC. CD4+PD-1+CXCR5+BCL6+GATA3+ cells
observed in the GC compartment are pointed by white arrows. (E) Bar graph showing the frequency of GATA3+ cells in different tonsillar CD4 T cell subsets,
analyzed by Cytof. The pair t-test was used for the statistical analysis. (F) Bar graphs depicting the frequency of CATA3+(GATA3-) PD1lo, PD1dim and PD1hi CD4
T cells and with respect to the expression of CXCR3 and CCR6.February 2021 | Volume 11 | Article 607626
Ioannidou et al. In Situ Tfh Cell Heterogeneityof Tfh cells in human lymphoid tissues. We have built
standardized protocols comprising eight panels including
several surface and nuclear markers to quantitatively evaluate
the frequencies, spatial distribution, co-localization, and
positioning of Tfh cells in healthy and neoplastic tissues.
Despite their unique anatomical localization compared to LNs,Frontiers in Immunology | www.frontiersin.org 11tonsils contain numerous follicular structures with relatively
high frequencies of Tfh cells which have been extensively
investigated (65–69). In line with previous studies (65, 66), we
found a considerable amount of CD3 T cells in the GC area with
the vast majority of them being CD4+ T cells. High expression of
PD-1, a widely used marker for Tfh cell identification, was
exclusively found in GC CD4 T cells with approximately 75%
of them characterized by a PD-1+ phenotype. No PD-1
expression was found in GC PAX5+ and FDC cells. Our data
are in agreement with previous studies (67, 69) and confirm the
value of PD-1 and CD4 as reference markers for the in situ
identification of Tfh cells. The orchestrated downregulation of
CCR7 and upregulation of CXCR5 is a driving force for the
trafficking of CD4 T cells into the follicular and GC areas (70).
Published data regarding the expression of CXCR5 in lymphoid
tissues and blood have been essentially derived from flow
cytometry analyses and frozen section immunohistochemistry
(71, 72), which have consistently shown high levels of expressionTABLE 5 | Demographic data, tissue information as well as the mutational status
of the three AITL LNs used are shown.
Case AITL 1 AITL 2 AITL 3
Gendre/Age M/70 F/83 M/77
Lymph Node cervical inguinal Not Specified
RHOA G17V VAF 3% 7% 6.9%
TET2 (exon3) VAF 3% 6% 11.4%
TET2 (exon10) VAF 4% 11% 15.4%
DNMT3A (exon15) VAF N/A 11% N/A
IDH2 (exon4) VAF N/A 9% 7.8%VAF, Variant Allele Frequency.A B
D
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FIGURE 5 | Tonsillar and AITL LN Tfh cell express different core signatures. (A) Bar graphs showing the expression (%) of individual Tfh cell markers with reference
(expression at 100%) to CD4+PD-1+ cells from the average of three human tonsils and three AITL lymph nodes. Collective data of all six multiplexed developed
panels were used. (B) Bar graphs showing the co-expression of individual markers defining particular Tfh cell signatures (Signature 1 CD4+PD-1+BCL6+CXCR5+
used panels: TFH1, TFH2, TFH3, TFH4, and TF, Signature 2 CD4+PD-1+BCL6+ICOS+CD10+, used panels: TFH1, TFH2, TFH3, and TF, and Signature 3 CD4+PD-
1+BCL6+CXCR5+CXCL13+GATA3+, used panels: TFH1, TFH2, TFH3, TFH4, and TF, 3). The dotted red lines define the area of co-expression for the most
abundant Tfh markers (PD1, BCL6, ICOS, CD10, CXCR5, and GATA3) referred to as “core signature”. (C) Pooled data showing the distribution of Tfh cells
expressing the signature 1 in different tonsillar ROIs. (D) Dot plots showing the frequency of Tfh cells expressing the signatures 1 and 2. Cells from three tonsils and
three lymph nodes were analyzed. (E) Representative immunofluorescence images of AITL 2 case stained with the TFH 2 panel. A merged image and the staining of
individual markers are shown.February 2021 | Volume 11 | Article 607626
Ioannidou et al. In Situ Tfh Cell Heterogeneityin Tfh cells particularly the GC ones. Our work is the first to
provide documentation of CXCR5 expression in Tfh cells by
using IHC/IF assays on FFPE tissues allowing for a good
morphologic discrimination and preservation of the tissue
structure. We found that CXCR5 was expressed by both B
cells, in accordance with flow cytometry data (73), as well as
by a subset of CD4+ T cells in lymphoid tissues, and from our
collective data the GC CD4+PD-1+ cells co expressed CXCR5 at
85% in alignment with the literature (2). ICOS, a critical factor
for Tfh cell differentiation/maintenance (56, 74) is highly
expressed in tonsillar Tfh cells, and accordingly we found high
expression of ICOS in the majority of GC PD-1+CD4+ T cells
(75, 76). Interestingly, a wide overlap between PD-1 and ICOS
expression in Tfh cells was observed pointing to a coordinated
function of these receptors. Investigation of their ligands (PD-L1,
ICOSL) expression could provide cues for the mode and time
order of their function. The simultaneous expression of PD-1
and ICOS can further inform for the local compartmentalization
of Tfh cells. By detecting different levels of single intensity of PD-
1, along with CXCR5, we noticed a tendency of Tfh cells with
PD-1 and CXCR5 high expression to be located at the outer rim
of the GC, near to the MZ. Therefore, our imaging platform can
provide meaningful data for the frequency/numbers of Tfh cell
populations with respect to their local compartmentalization.
The combined analysis of several markers revealed the
presence of tonsillar Tfh cell subsets at least at the phenotypic
level. We identified a “core” of markers (PD-1, ICOS, CXCR5,
CD10, BCL6, and GATA3, Figure 5A) that we call the “core
signature” and could be used in future studies for the tracking of
Tfh cell subsets at tissue level. Whether this localization profile is
associated with different functionality of the described Tfh cell
subsets is not known and needs further investigation. Our
imaging analysis revealed that approximately 20% of Tfh cells
were positive for CXCL-13. CXCL-13, the ligand of CXCR5, is
produced by several cell types both in the extrafollicular (77) and
intrafollicular area (78). Its autocrine and paracrine functions
make it a major player for the organization of B-cell follicles and
GCs. Although our assays cannot address whether the CXCL13 is
produced or just bound to Tfh cells, use of functional markers
like the CXCL13 chemokine in combination with the
aforementioned receptors can guide the investigation of Tfh
heterogeneity both at phenotypic and functional level.
The lineage origin and differentiation commitment of human
Tfh cells is poorly known. Studies using mouse models have
shown that naïve CD4 T cells acquire lineage-depend effector
functions after encounter of a foreign antigen presented by
antigen presenting cells (APC). The initial description of Th1,
Th2, and Th17 (79) has been followed by the identification of
several other CD4+ T cell types including Treg, Th9, and Tfh
subtypes (20, 80). It is generally considered that the commitment
into the different subtypes is dictated by the expression of
lineage-specifying transcription factors such as TBET, GATA3,
BCL6, or RORgt conferring to the subtype unique sets of
phenotypes, functions, and selective effector cytokines
production while suppressing their differentiation into an
alternative subtype (81–85). GATA3 is a transcription factorFrontiers in Immunology | www.frontiersin.org 12important for the differentiation of several cell lineages including
breast epithelia and urothelial cells (86) as well as subsets of T
lymphocytes for Th2 maturation (85). Its role in Tfh cell
differentiation is not well understood as both positive (87, 88)
and negative roles (35) have been proposed. Our data show that
about one third of CD4+ PD1+ GC cells in the tonsil co
expressed CXCR5, BCL6 and GATA3 implying an important
role for GATA3 for human Tfh cell development. Our Cytof
analysis revealed that the majority of tonsillar GATA3+ Tfh cells
express a Tfh2 phenotype (CXCR3-CCR6-), while an evident
population (approximately 20%) express a Tfh1 (CXCR3
+CCR6-) profile (18). Whether the heterogeneity of circulating
Tfh cells (89) mirrors the one found in follicular Tfh cells is not
known. The lineage relationship between Tfh subsets expressing
similar profiles (Tfh1, Tfh2) in blood and lymphoid organs
remains to be elucidated.
Our data are in line with recent studies suggesting that the
orchestrated activity of multiple transcription factors rather than
a “unique, master” regulator is needed for the development of T
helper cell subtypes (90, 91). A recently proposed model implies
that an epigenetic mechanism orchestrating a transient
expression of TBET, GATA3, or RORgt together with BCL6 at
early stage of differentiation in Tfh cells, could justify their
underlying ability to produce other lineages’ specific cytokines
(92). Our data showed a trend for GATA3 polarization towards
the light zone. The expression of GATA3 in human Tfh cell
subsets raising questions regarding their origin from further Th2
differentiated cells or the irreversible differentiation fate of the
CD4 T cells. In fact, increasing evidence supports an emerging
model suggesting that upon changing conditions of the
microenvironment in their surroundings, effector CD4 T cells
could effectively rewire their lineage-specific functional program
having previously preserved traces of other lineage-defining
factors (31, 92).
Our previous work has provided critical data showing the
origin of AITL from Tfh cells (42). Others later expanded these
observations, resulting in the concept now adopted by the WHO
classification, that the nodal lymphomas of Tfh derivation
comprise a spectrum of diseases including AITL, follicular T-cell
lymphoma, and other nodal lymphomas with a Tfh phenotype.
Importantly, since we have described the mutational status of
AITL as well as other lymphomas of Tfh origin (93), we were thus
interested to illustrate the frequencies and co-expressions of Tfh
neoplastic cells in situ. The calculated frequencies of Tfh cells in
AITL LNs (Table 3) were higher than the estimated neoplastic
cells (Table 4). Despite the small size of the analyzed LNs, an
association between the prevalence of these two cell types was
observed. Further studies aiming to establish such correlation are
needed. Although the frequency of Tfh cells was higher in AITL
compared to tonsils, the percentage of AITL Tfh cells expressing a
BCL6hi phenotype was reduced. Whether this is due to an over
expansion of the AITL BCL6lo Tfh cells or a defected expression of
BCL6 per se needs further investigation. Furthermore, the lower
frequency of CXCR5hi AITL Tfh cells was associated with a higher
frequency of CXCL13hi Tfh cells compared to tonsils. We
hypothesize that this profile could represent a higher rate ofFebruary 2021 | Volume 11 | Article 607626
Ioannidou et al. In Situ Tfh Cell Heterogeneityrecognition of CXCR5 by its ligand ultimately leading to
downregulation/recycling of the receptor. In line with this, a
relatively high frequency of Tfh cells co-expressing CXCR5 and
CXCL13 was found in AITL compared to tonsils, suggesting an
important role for the CXCR5/CXCl13 axis as regulator of the Tfh
cell trafficking and positioning in AITL LNs. CD30, a receptor
found on activated T cells and widely used for diagnosis of
peripheral T lymphomas (61, 62, 94), was readily found in AITL
Tfh cells but it was almost absent in their tonsillar counterparts.
Interestingly, the majority of CD30hi Tfh cells were expressing a
BCL6hi phenotype too, indicating a possible role of CD30 in the
differentiation process of AITL Tfh cells. Although the WHO
criteria specifically state that expression of at least three Tfh
markers is required for assignment of a Tfh phenotype (38, 95),
we detected a high level of heterogeneity concerning six Tfh
markers, which were robustly co expressed in the tumor niche,
that is to say CD4, PD-1, CXCR5, ICOS, Bcl6, and CXCL13. In a
recent study, two AITL cases were analyzed using multiplexed
quantitative immunohistochemistry techniques and one panel to
simultaneously stain for a collection of relevant markers in
lymphoid tissue to determine the expression of marker of
interest in malignant cells, such as the CD4, PD-1, and BCL6.
On average, 45.5% of the CD4+ T cells in the samples were
positive for PD-1, while 26% were positive for BCL6 (96). Despite
the limited number of samples analyzed, which precludes the
extraction of robust conclusions, we found a differential
representation of particular Tfh cell subtypes/signatures between
tonsils and AILT LNs, a finding that could trigger further
investigation of the Tfh heterogeneity in relevant subjects. The
differential representation of Tfh cell subsets was also associated
with an altered distribution of Tfh cells within the tumor area
compared to tonsils too. An atypical, less structured distribution of
Tfh cells in AILT was more evident in the donors with higher
frequency of tumor cells and higher prevalence of unique
mutations found in AILT donors. Our data urge further
combined analysis of particular Tfh cell populations, their
spatial positioning and genetic background of neoplastic cells
that could establish an association between these biological
parameters and a possible role in disease progression.
In conclusion, using tonsils, we have optimized a multiplex IF
protocol for mapping the cellular distribution by multiple staining
in a single section, conserving limited clinical material, while
enabling spatial resolution of co-localized antigens. Despite the
limited number of tissues analyzed, our data provide a proof of
concept for such tissue analysis aiming to understand the
heterogeneity of the Tfh cell compartment in health and disease.
The described phenotypes and tissue signatures can provide the
base for the development of antibody panels with higher
complexity and integration with other imaging platforms (e.g.,
multiplexed confocal imaging) for further investigation of Tfh cell
heterogeneity. Our data suggest that the combined investigation of
spatial positioning and in situ phenotyping (surface receptors,
functional biomarkers, nuclear factors) of Tfh cells can provide a
comprehensive analysis for their heterogeneity and plasticity in
relevant diseases like AILT. This is particularly crucial for
diagnostics and classifying disease state in the future.Frontiers in Immunology | www.frontiersin.org 13DATA AVAILABILITY STATEMENT
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Supplementary Figure 1 | Overview of the workflow of advanced multiplexed
immunohistochemistry from staining to image analysis.
Supplementary Figure 2 | Monoplexed and multiplexed immunohistochemistry
in tonsils. (A) Representative examples of histological evaluation from IHC (upper
panel) and monoplex IF (lower panel) with optimal staining pattern, intensity, and
morphology. (B) Representative images generated with the TFH 3 mIHC panel.
Supplementary Figure 3 | (A) Mean expression of individual markers in the
three tonsils (expressed as % of the GC cells) from the different mIHC panels.
(B) Expression of markers used in different tonsils among all mIHC panels. StatisticalFebruary 2021 | Volume 11 | Article 607626
Ioannidou et al. In Situ Tfh Cell Heterogeneityanalyses were performed using one-way ANOVA and non-parametric tests. ***P ≤
0.001, **P ≤ 0.01, *P ≤ 0.05.
Supplementary Figure 4 | (A) Identification of extrafollicular (ExtraFC), germinal
center (GC) and mantle zone (MZ) areas in a tonsillar follicle (right panel). A merged
image with all markers used is shown in the left panel. Follicular Tfh cells divided into
two subsets based on their localization, GC, and follicular mantle zone cells.
(B) Cells with differential expression of CXCR5 (high-red, medium-orange, and low-
yellow) in the three different compartments are shown. (C) The localization of PD-1
high (red), medium (orange), and low (yellow) cells in the same follicular areas is
shown. (D) quantification of follicular cells with respect to expression level of PD-1
and CXCR5 in GC, MZ and ExtraFC is shown.
Supplementary Figure 5 | The gating scheme for the Cytof analysis of tonsillar
Tfh cell subsets is shown. N tonsils were used for the analysis.
Supplementary Figure 6 | An overview of the BCL6 staining for the whole LN
imaged area from each donor is shown (upper row). Our analysis program (inFORM)Frontiers in Immunology | www.frontiersin.org 14allows the overview presentation only for imaging data before processing
(unmixing). BCL6 label was the only marker used without crosstalk signal with the
rest of the markers. The expression of BCL6 (in red) and PD1 (green) (post-
processing data) in a small area (red boxes) as well as zoomed images (white boxes)
are shown for each donor. The images show that the sequestration of BCL6 is
associated with that of TFH (PD1+) cells.
Supplementary Figure 7 | (A) Representative immunofluorescent images
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